NOAH-AFNET 6
2023
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High-Rate Episodes
In 2,536 patients with device-detected atrial high-rate episodes, edoxaban did not reduce cardiovascular death, stroke, or systemic embolism compared with placebo.
Result
Efficacy: Composite of cardiovascular death, stroke, or systemic embolismHR 0.81 (95% CI 0.60-1.08)
Safety: Death or major bleedingHR 1.31 (95% CI 1.02-1.67)
Below 1 favours edoxaban, above 1 favours placebo.
Event rates Edoxaban 3.2 vs placebo 4.0 per 100 patient-years (composite of cardiovascular death, stroke, or systemic embolism)
Also reported: Neutral.
- Subtopic
- DOAC
- Design
- Double-blind placebo-controlled RCT, terminated early
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 AF
- Source
- Kirchhof P, et al. N Engl J Med. 2023;389(13):1167-1179.doi 10.1056/NEJMoa2303062
Discussion & critique
Stopped early for safety with a low event rate, so a small benefit cannot be fully excluded. Suggests anticoagulation of short atrial high-rate episodes causes net harm without documented AF.